Rheumatol Int. 2012 Apr;32(4):1095-7. doi: 10.1007/s00296-011-1855-5. Epub 2011 Mar 23.
Familial mediterranean fever (FMF) is an autoinflammatory disease characterized by recurrent attacks of fever, peritonitis, pleuritis, and genetically by autosomal recessive inheritance. The major renal involvement in FMF is the occurrence of amyloidosis that can be prevented by a daily regimen of colchicine. About 5-10% of cases with familial mediterranean fever may be resistant to colchicine. In literature, there is a controversy about the treatment of FMF patients resistant to colchicine. We describe a case with FMF, proteinuria, and bilateral sacroiliitis, which responded to anti-TNF (tumor necrosis factor)-alpha therapy with infliximab and etanercept.
家族性地中海热（FMF）是一种自身炎症性疾病，其特征为反复发作的发热、腹膜炎、胸膜炎，并呈常染色体隐性遗传。FMF 的主要肾脏受累是淀粉样变性的发生，这种变性可以通过每日服用秋水仙碱来预防。大约 5-10%的家族性地中海热病例可能对秋水仙碱耐药。在文献中，对于秋水仙碱耐药的 FMF 患者的治疗存在争议。我们描述了一例 FMF 患者，伴有蛋白尿和双侧骶髂关节炎，对英夫利昔单抗和依那西普的抗 TNF（肿瘤坏死因子）-α治疗有反应。
